TY - JOUR
T1 - Mn(III) porphyrins as potential MRI contrast agents for diagnosis and MRI-guided therapy
AU - Geraldes, Carlos F.G.C.
AU - Castro, M. Margarida C.A.
AU - Peters, Joop A.
N1 - Accepted Author Manuscript
PY - 2021
Y1 - 2021
N2 - Mn(III) porphyrins have great potential as Gd-free MRI contrast agents because both the cation and the ligand have interesting properties. The redox properties of the Mn(III)-ion can be exploited for the preparation of reactive oxygen species for therapy. Moreover, the porphyrin ligand allows these complexes to have a high affinity for tumor tissues. The inherent properties of the porphyrin ligands make these systems attractive for photothermal, photodynamic, and sonodynamic therapies. Therefore, these systems are attractive for the development of theranostics for MRI-guided therapy. For the magnetic field strengths at which most clinical MRI machines operate at present (0.5–1.5 T), the longitudinal relativity of low-molecular-weight complexes is even higher than that of the classical Gd-based contrast agents. This review gives an overview of the developments in the field of Mn(III) porphyrin contrast agents during the last 30 years.
AB - Mn(III) porphyrins have great potential as Gd-free MRI contrast agents because both the cation and the ligand have interesting properties. The redox properties of the Mn(III)-ion can be exploited for the preparation of reactive oxygen species for therapy. Moreover, the porphyrin ligand allows these complexes to have a high affinity for tumor tissues. The inherent properties of the porphyrin ligands make these systems attractive for photothermal, photodynamic, and sonodynamic therapies. Therefore, these systems are attractive for the development of theranostics for MRI-guided therapy. For the magnetic field strengths at which most clinical MRI machines operate at present (0.5–1.5 T), the longitudinal relativity of low-molecular-weight complexes is even higher than that of the classical Gd-based contrast agents. This review gives an overview of the developments in the field of Mn(III) porphyrin contrast agents during the last 30 years.
KW - Chemotherapy
KW - Photodynamic therapy
KW - Photothermal therapy
KW - Relaxivity
KW - Theranostics
UR - http://www.scopus.com/inward/record.url?scp=85109085911&partnerID=8YFLogxK
U2 - 10.1016/j.ccr.2021.214069
DO - 10.1016/j.ccr.2021.214069
M3 - Review article
AN - SCOPUS:85109085911
VL - 445
JO - Coordination Chemistry Reviews
JF - Coordination Chemistry Reviews
SN - 0010-8545
M1 - 214069
ER -